112 related articles for article (PubMed ID: 29307515)
1. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
2. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
[TBL] [Abstract][Full Text] [Related]
3. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis.
Komiyama S; Okusaka T; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Morizane C; Ueno H; Sukeda A; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Hiraoka N; Shimada K
Intern Med; 2024 Apr; 63(7):891-901. PubMed ID: 37612088
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of systemic immune-inflammation index in patients with nonfunction pancreatic neuroendocrine tumor undergoing surgical resection.
Chen G; Liu L; Tan C; Tan Q; Chen Y; An X; Liu X; Wang X
Cancer Med; 2024 Apr; 13(7):e7114. PubMed ID: 38553949
[TBL] [Abstract][Full Text] [Related]
6. Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 May; 126(5):326-335. PubMed ID: 29451738
[TBL] [Abstract][Full Text] [Related]
7. Machine Learning Methods Based on CT Features Differentiate G1/G2 From G3 Pancreatic Neuroendocrine Tumors.
Chen HY; Pan Y; Chen JY; Chen J; Liu LL; Yang YB; Li K; Ma Q; Shi L; Yu RS; Shao GL
Acad Radiol; 2024 May; 31(5):1898-1905. PubMed ID: 38052672
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.
Halfdanarson TR; Rabe KG; Rubin J; Petersen GM
Ann Oncol; 2008 Oct; 19(10):1727-33. PubMed ID: 18515795
[TBL] [Abstract][Full Text] [Related]
9. When Should Lymphadenectomy Be Performed in Non-Metastatic Pancreatic Neuroendocrine Tumors? A Population-Based Analysis of the German Clinical Cancer Registry Group.
Abdalla TSA; Bolm L; Klinkhammer-Schalke M; Zeissig SR; Kleihues van Tol K; Bronsert P; Litkevych S; Honselmann KC; Braun R; Gebauer J; Hummel R; Keck T; Wellner UF; Deichmann S
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275882
[TBL] [Abstract][Full Text] [Related]
10. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.
Sadot E; Reidy-Lagunes DL; Tang LH; Do RK; Gonen M; D'Angelica MI; DeMatteo RP; Kingham TP; Groot Koerkamp B; Untch BR; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2016 Apr; 23(4):1361-70. PubMed ID: 26597365
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine neoplasms of the gallbladder: A single institute analysis of outcomes and prognostic factors.
Nandy K; Patkar S; Yadav S; Ostwal V; Ramaswamy A; Bhargav P; Goel M
J Surg Oncol; 2024 May; 129(6):1121-1130. PubMed ID: 38348696
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract][Full Text] [Related]
13. Factors Affecting Nonfunctioning Small Pancreatic Neuroendocrine Neoplasms and Proposed New Treatment Strategies.
Hijioka S; Yamashige D; Esaki M; Honda G; Higuchi R; Masui T; Shimizu Y; Ohtsuka M; Kumamoto Y; Katanuma A; Gotohda N; Akita H; Unno M; Endo I; Yokoyama Y; Yamada S; Matsumoto I; Ohtsuka T; Hirano S; Yasuda H; Kawai M; Aoki T; Nakamura M; Hashimoto D; Rikiyama T; Horiguchi A; Fujii T; Mizuno S; Hanada K; Tani M; Hatori T; Ito T; Okuno M; Kagawa S; Tajima H; Ishii T; Sugimoto M; Onoe S; Takami H; Takada R; Miura T; Kurita Y; Kamei K; Mataki Y; Okazaki K; Takeyama Y; Yamaue H; Satoi S;
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38615727
[TBL] [Abstract][Full Text] [Related]
14. Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.
Olearska H; Sowa-Staszczak A; Morawiec-Sławek K; Kurzyńska A; Kolasa M; Tkacz E; Szumińska M; Hubalewska-Dydejczyk A; Opalinska M
Endokrynol Pol; 2024; 75(1):102-108. PubMed ID: 38497396
[TBL] [Abstract][Full Text] [Related]
15. The latest exploration of staging and prognostic classification for pancreatic neuroendocrine tumors: a large population-based study.
Gao S; Pu N; Liu L; Li C; Xu X; Wang X; Lou W
J Cancer; 2018; 9(9):1698-1706. PubMed ID: 29760809
[No Abstract] [Full Text] [Related]
16. Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E; Kjellman M; Knigge U; Gronbaek H; Schalin-Jäntti C; Welin S; Sorbye H; Del Pilar Schneider M; Belusa R;
J Neuroendocrinol; 2022 Jul; 34(7):e13176. PubMed ID: 35829662
[TBL] [Abstract][Full Text] [Related]
17. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.
Ito T; Igarashi H; Jensen RT
J Gastroenterol; 2012 Sep; 47(9):941-60. PubMed ID: 22886480
[TBL] [Abstract][Full Text] [Related]
18. Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe.
Jann H; Krieg S; Krieg A; Eschrich J; Luedde T; Kostev K; Loosen S; Roderburg C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7557-7563. PubMed ID: 36971798
[TBL] [Abstract][Full Text] [Related]
19. Impact of grade on workup of rectal neuroendocrine tumors: a retrospective cohort study : Grade impact on workup of rectal NETs.
Watanabe A; Rai S; Yip L; Brown CJ; Loree JM; Stuart HC
World J Surg Oncol; 2024 Apr; 22(1):98. PubMed ID: 38627724
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3).
Apostolidis L; Dal Buono A; Merola E; Jann H; Jäger D; Wiedenmann B; Winkler EC; Pavel M
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
